BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28725988)

  • 21. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
    Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S
    J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
    Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
    J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
    Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
    Karantanis D; O'eill BP; Subramaniam RM; Witte RJ; Mullan BP; Nathan MA; Lowe VJ; Peller PJ; Wiseman GA
    Nucl Med Commun; 2007 Nov; 28(11):834-41. PubMed ID: 17901765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic value of PET-CT in patients with diffuse large B-cell lymphoma].
    Ding C; Li T; Sun J; Yang W; Ding Q; Xu X
    Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):923-7. PubMed ID: 25623768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
    Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
    Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.
    Wei WX; Huang JJ; Li WY; Zhang X; Xia Y; Jiang WQ; Fan W; Li ZM
    Chin J Cancer; 2015 Dec; 34(12):608-13. PubMed ID: 26630874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].
    Ying ZT; Mi L; Wang XJ; Zhang YW; Yang Z; Song YQ; Wang XP; Zheng W; Lin NJ; Tu MF; Xie Y; Ping LY; Zhang C; Liu WP; Deng LJ; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):382-386. PubMed ID: 29779346
    [No Abstract]   [Full Text] [Related]  

  • 33. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
    Zinzani PL; Gandolfi L; Broccoli A; Argnani L; Fanti S; Pellegrini C; Stefoni V; Derenzini E; Quirini F; Baccarani M
    Cancer; 2011 Mar; 117(5):1010-8. PubMed ID: 20960498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Our experience with the treatment of primary lymphomas of the central nervous system].
    Motyčková M; Smolej L; Belada D; Malý J; Zák P
    Vnitr Lek; 2012 Dec; 58(12):915-21. PubMed ID: 23427949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
    Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
    J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
    Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
    Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interim18 F-FLUORO-2-deoxy-d-glucose positron emission tomography scan/computed tomography scan in diffuse large B cell lymphoma-as a prognostic tool.
    Basit A; Siddiqui N; Muzaffar N; Awan UK; Bashir H; Khan SA; Hameed A
    J Pak Med Assoc; 2016 Apr; 66(4):380-6. PubMed ID: 27122261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J; Qiao W; Wang C; Wang T; Xing Y
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.